Video
Study finds UGN-102 well-tolerated in patients with NMIBC
Author(s):
Video Player is loading.
In this video, William C. Huang, MD, discusses the findings and takeaways of a recent phase 2b trial published in the Journal of Urology, which investigates the agent UGN-102 as a treatment for patients with non–muscle-invasive bladder cancer (NMIBC). Huang is a professor in the departments of urology and radiology at the New York University Grossman School of Medicine and the chief of urology at Tisch Hospital, New York City.
Related Videos
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Sima Porten, MD, on gene-environment interactions in bladder cancer development
How rBCG EAP could open up access for Anktiva in bladder cancer
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Related Content
